Affinity Asset Advisors’s Immunovant IMVT Stock Holding History

Affinity Asset Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-78,000	Closed	-$2.22M	–	91
2024 Q3	$2.22M	Buy	78,000 +23,700	+44%	+$699K	0.3%	64
2024 Q2	$1.43M	Sell	54,300 -90,100	-62%	-$2.56M	0.17%	75
2024 Q1	$4.67M	Buy	+144,400	New	+$5.27M	0.58%	52
2021 Q4	–	Sell	-30,000	Closed	-$261K	–	63
2021 Q3	$261K	Hold	30,000	–	–	0.07%	70
2021 Q2	$317K	Sell	30,000 -40,000	-57%	-$559K	0.11%	66
2021 Q1	$1.12M	Buy	+70,000	New	+$1.85M	0.38%	46

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Affinity Asset Advisors's IMVT Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Immunovant (IMVT) stake by 50% in Q1 2026, selling an estimated $2.59M and leaving 100,000 shares worth $2.48M. The position accounts for 0.13% of the portfolio, ranked #91.

Affinity Asset Advisors first reported a position in IMVT in Q4 2020 and has held it in 12 quarters since. The position peaked at $14.5M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Affinity Asset Advisors held 100,000 shares of Immunovant worth $2.48M as of Q1 2026.
Affinity Asset Advisors sold 100,000 Immunovant shares in Q1 2026, an estimated $2.59M.
Immunovant made up 0.13% of Affinity Asset Advisors's portfolio in Q1 2026, its #91 holding.
Affinity Asset Advisors first reported a position in Immunovant in Q4 2020 and has held it in 12 quarters since.
Affinity Asset Advisors's Immunovant position peaked at $14.5M in Q4 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.